Based on the clear role for glucagon in the pathogenesis of diabetes, glucagon-blocking therapies have been pursued as adjuncts to therapy. Glucagon antagonism^[@R4]--[@R9]^ and knockdown of the glucagon receptor^[@R10],[@R11]^ have shown glucose-lowering effects; however, these agents increase liver enzymes^[@R7],[@R8]^ by an unknown mechanism. Conversely, a dual glucagon-like peptide-1/glucagon receptor agonist lowers blood glucose, associated with increased energy expenditure and weight loss^[@R12]^. Together, these data suggest a role for glucagon to promote hepatic mitochondrial fat oxidation in addition to hepatic gluconeogenesis.

Glucagon stimulates hepatic glycogenolysis and gluconeogenesis, the latter believed to occur largely through transcriptional regulation. Hepatic calcium signaling is integral to transcriptional regulation of gluconeogenesis: inhibition or deletion of liver Ca^2+^/calmodulin-dependent protein kinase II (CAMKII) results in reduced gluconeogenic protein expression in mouse livers and associated reductions in plasma glucose and insulin concentrations^[@R13]--[@R15]^. Type I InsP~3~R is the isoform primarily responsible for mitochondrial calcium signaling in hepatocytes^[@R16]^. Wang et al. showed that knocking down InsP~3~R-I reduced glucose production in isolated hepatocytes^[@R14]^; however, no studies have fully characterized the role of InsP~3~R signaling in glucagon-stimulated hepatic gluconeogenesis *in vivo*.

In order to examine the potential calcium dependence of the acute response to glucagon, we studied overnight-fasted, glycogen-depleted, liver-specific InsP~3~R-I knockout (InsP~3~R-I KO) mice and their weight-matched wild-type (WT) littermates ([Extended Data Figure 1a](#F4){ref-type="fig"}). InsP~3~R-I KO mice exhibited a marked reduction in hepatic InsP~3~R-I protein expression ([Extended Data Figure 1b](#F4){ref-type="fig"}; full gels for all blots in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). We examined subcellular fractions in primary hepatocytes and found that InsP~3~R-I was associated with mitochondria, while InsP~3~R-II was not, and InsP~3~R-III was not detected ([Extended Data Figure 1c](#F4){ref-type="fig"}), consistent with prior data showing that InsP~3~R-I is primarily responsible for mitochondrial calcium signals^[@R16]^. We then treated mice with an acute infusion of glucagon, which modestly increased plasma glucose and insulin concentrations in WT but not KO mice, associated with increased InsP~3~R-I phosphorylation ([Figure 1a](#F1){ref-type="fig"}--[c](#F1){ref-type="fig"}, [Extended Data Figure 1c](#F4){ref-type="fig"}). CREB-regulated transcriptional coactivator-2 (CRTC2) phosphorylation was decreased with glucagon in both genotypes ([Extended Data Figure 1d](#F4){ref-type="fig"}), consistent with previous literature^[@R14]^. Glucagon increased cAMP concentrations and protein kinase A (PKA) activity in both genotypes, dissociating these mediators from glucagon-induced changes in plasma glucose ([Figure 1d](#F1){ref-type="fig"}--[e](#F1){ref-type="fig"}). Consistent with a previous report^[@R13]^, glucagon stimulated CAMKII but not CAMKIV phosphorylation in an InsP~3~R-I-dependent manner ([Figure 1f](#F1){ref-type="fig"}, [Extended Data Figure 1e](#F4){ref-type="fig"}). These data imply that InsP~3~R-I activation and CAMKII activity are required for glucagon's acute effect to stimulate hepatic glucose production (HGP), which can be attributed almost entirely to gluconeogenesis in this glycogen-depleted state^[@R17]^. Indeed, we measured \~25% increases in *in vivo* HGP, which could be attributed to increased hepatic V~PC~ flux associated with amino acid depletion without alterations in hepatic glycogen content ([Figure 1g](#F1){ref-type="fig"}--[h](#F1){ref-type="fig"}, [Extended Data Figure 1f](#F4){ref-type="fig"}--[m](#F4){ref-type="fig"}, [Supplementary Table 1](#SD3){ref-type="supplementary-material"}--[2](#SD3){ref-type="supplementary-material"}). The *in vivo* HGP data were mirrored by two-fold increases in both HGP and V~PC~ flux in isolated hepatocytes from WT but not KO mice incubated with glucagon ([Extended Data Figure 1n](#F4){ref-type="fig"}--[o](#F4){ref-type="fig"}). Insulin's ability to suppress HGP and V~PC~ flux was unaltered in KO hepatocytes, and malic enzyme activity was dissociated from HGP by treatment with a malic enzyme inhibitor ([Extended Data Figure 1p](#F4){ref-type="fig"}--[s](#F4){ref-type="fig"}). Finally, *in vivo* studies with somatostatin and replacement insulin infusion to mimic basal portal vein insulin concentrations (\~85--90 pM in both genotypes) revealed that changes in plasma insulin could not explain glucagon's effect to stimulate HGP and V~PC~ only in WT mice ([Extended Data Figure 1t](#F4){ref-type="fig"}--[x](#F4){ref-type="fig"}).

To further explore the calcium-dependent mechanism by which glucagon stimulates HGP and V~PC~ flux, we treated hepatocytes with ET-18-OCH~3~ or U-73122, two phospholipase C (PLC) antagonists, and found that both agents inhibited glucose production and V~PC~ flux in WT but not InsP~3~R-I KO hepatocytes ([Extended Data Figure 2a](#F5){ref-type="fig"}--[d](#F5){ref-type="fig"}). Similarly, a PKA inhibitor, H-89, abrogated glucagon's ability to stimulate glucose production and V~PC~ only in WT hepatocytes, demonstrating that both the PLC and PKA pathways are required to activate gluconeogenesis in response to glucagon via InsP~3~R-I signaling ([Extended Data Figure 2e](#F5){ref-type="fig"}--[f](#F5){ref-type="fig"}). Next to specifically confirm the role of InsP~3~R-I to promote HGP, we treated hepatocytes with vasopressin, an activator of the InsP~3~ receptor, and found that this agent recapitulated the effect of glucagon to increase HGP and V~PC~ ([Extended Data Figure 2g](#F5){ref-type="fig"}--[h](#F5){ref-type="fig"}). However, small molecule inhibitors of InsP~3~ (2-aminoethoxydiphenyl borate \[2-ABP\] and caffeine), CAMKII/IV (KN-93), and the SERCA pump (thapsigargin), inhibited glucagon's effect to stimulate HGP and V~PC~ ([Extended Data Figure 2i](#F5){ref-type="fig"}--[p](#F5){ref-type="fig"}), suggesting that maintaining a normal balance of calcium throughout the cell is required for normal InsP~3~R-I signaling. None of these agents had any effect in InsP~3~R-I KO mice, indicating that InsP~3~R-II and -III do not restore glucose production in the absence of InsP~3~R-I in liver.

Surprisingly the observed increases in rates of HGP occurred in the absence of any effect of glucagon to acutely increase hepatic gluconeogenic mRNA or protein expression *in vivo*. However, glucagon infusion increased hepatic long-chain acyl-CoA and acetyl-CoA content by 35--60% ([Figure 1i](#F1){ref-type="fig"}--[j](#F1){ref-type="fig"}, [Extended Data Figure 3a](#F6){ref-type="fig"}--[e](#F6){ref-type="fig"}). These increases in hepatic long-chain- and acetyl-CoA concentrations were dissociated from phosphorylation of both acetyl-CoA carboxylase and 5' AMP-activated protein kinase (AMPK), both of which were increased in InsP~3~R-I KO mice but not in WT mice ([Extended Data Figure 3f](#F6){ref-type="fig"}--[g](#F6){ref-type="fig"}), likely reflecting the interplay between glucagon's ability to promote the phosphorylation of both enzymes and the ability of hyperinusulinemia, which was observed only in WT mice infused with glucagon, to suppress it. Hepatic long-chain acyl-CoA and acetyl-CoA content increased in WT mice infused with glucagon despite reduced plasma NEFA concentrations in glucagon-treated WT mice ([Extended Data Figure 3h](#F6){ref-type="fig"}), consistent with glucagon stimulation of intrahepatic but not white adipose tissue (WAT) lipolysis. As acetyl-CoA is an allosteric activator of PC^[@R18]^, the increase in hepatic acetyl-CoA content observed with glucagon infusion could explain the increases in V~PC~ and HGP rates that occurred following glucagon treatment in WT mice. These changes occurred independently of any changes in hepatic malonyl-CoA content ([Extended Data Figure 3i](#F6){ref-type="fig"}), indicating that malonyl-CoA suppression of carnitine palmitoyl transferase-I was not responsible for glucagon stimulation of hepatic mitochondrial β-oxidation under these conditions.

To further understand the physiologic role of glucagon-induced HGP, we fasted WT and InsP~3~R-I KO mice for 48 hr. In the starved state, despite 70--90% increases in plasma glucagon concentrations in the tail vein and portal vein, KO mice manifested relative reductions in plasma glucose and insulin concentrations associated with reductions in hepatic long-chain CoA and acetyl-CoA content without any changes in hepatic malonyl-CoA content ([Extended Data Figure 3j](#F6){ref-type="fig"}--[o](#F6){ref-type="fig"}). These data demonstrate a critical role for InsP~3~R-I in maintenance of euglycemia during starvation.

We next hypothesized that InsP~3~R-I stimulation of intrahepatic lipolysis may explain the observed increases in hepatic acetyl-CoA content and V~PC~ flux following glucagon treatment. Consistent with this hypothesis, hepatic adipose triglyceride lipase (ATGL) S406 phosphorylation, which has been shown to regulate ATGL activity^[@R19]^, was increased three-fold by glucagon in WT but not KO mouse livers ([Figure 2a](#F2){ref-type="fig"}). In contrast, hormone-sensitive lipase (HSL) phosphorylation was increased by glucagon in both genotypes, dissociating HSL activity from glucagon activation of HGP and V~PC~ ([Extended Data Figure 4a](#F7){ref-type="fig"}). *In vitro* studies revealed 60--100% increases in NEFA and glycerol production with glucagon treatment in WT but not InsP~3~R-I deficient hepatocytes ([Extended Data Figure 4b](#F7){ref-type="fig"}--[c](#F7){ref-type="fig"}). Plasma NEFA concentrations were unchanged by glucagon infusion in mice treated with somatostatin ([Extended Data Figure 4d](#F7){ref-type="fig"}). These data suggest that, while glucagon may promote lipolysis when infused at markedly supraphysiologic doses^[@R20]^, under physiologic conditions (intact β-cell function, physiologic concentrations of glucagon), glucagon does not directly affect WAT lipolysis^[@R21]--[@R23]^. Confirming the requirement for glucagon-stimulated intrahepatic lipolysis to promote gluconeogenesis, glucagon had no effect in hepatocytes treated with atglistatin, a small molecule inhibitor of ATGL. Similarly, InsP~3~ agonism recapitulated the effect of glucagon to stimulate intrahepatic lipolysis, while inhibitors of InsP~3~, CAMKII/IV, PLC, PKA, and the SERCA pump inhibited the effects of glucagon to stimulate intrahepatic lipolysis and HGP/V~PC~ ([Figure 2b](#F2){ref-type="fig"}, [Extended Data Figure 4e](#F7){ref-type="fig"}--[n](#F7){ref-type="fig"}). To examine the impact of glucagon stimulation of intrahepatic lipolysis *in vivo*, we knocked down ATGL in a liver-specific manner in WT and InsP~3~R-I knockout littermates ([Extended Data Figure 5a](#F8){ref-type="fig"}--[c](#F8){ref-type="fig"}). ATGL knockdown abrogated the effects of glucagon to stimulate HGP, V~PC~ flux, and long-chain- and acetyl-CoA content in WT mice ([Figure 2c](#F2){ref-type="fig"}--[h](#F2){ref-type="fig"}), demonstrating a critical role for stimulation of intrahepatic lipolysis in mediating the increases in each parameter resulting from glucagon infusion. These alterations in hepatic gluconeogenesis were again dissociated from changes in hepatic glycogen content or hepatic gluconeogenic protein expression. In addition, the alterations in hepatic gluconeogenesis rates were dissociated from WAT lipolysis and from hepatic malonyl-CoA content ([Extended Data Figures 5d](#F8){ref-type="fig"}--[j](#F8){ref-type="fig"}). Taken together these data identify a novel mechanism by which glucagon stimulates hepatic gluconeogenesis by promoting intrahepatic lipolysis through stimulation of ATGL in an InsP~3~R-I/Ca^2+^/calcium-dependent manner, thereby increasing hepatic acetyl-CoA and gluconeogenesis via allosteric activation of pyruvate carboxylase.

Next, we hypothesized that glucagon may also stimulate hepatic mitochondrial oxidation via InsP~3~R-I. Indeed, glucagon increased both mitochondrial and cytosolic calcium signaling in hepatocytes from WT mice, with InsP~3~R-I mice manifesting a reduced response to glucagon likely attributable to activity of the II and/or III isoforms of the InsP~3~ receptor. Vasopressin caused a similar increase in cytosolic and mitochondrial calcium signaling in WT but not InsP~3~R-I KO mice. However, incubation of WT hepatocytes with a PLC inhibitor completely abrogated the mitochondrial and cytosolic calcium responses to glucagon. PKA inhibition reduced the amplitude of the mitochondrial but not the cytosolic calcium response, but lowered the percentage of responding cells by 75% ([Extended Data Figure 6a](#F9){ref-type="fig"}--[m](#F9){ref-type="fig"}). *Ex vivo* Positional Isotopomer NMR Tracer Analysis (PINTA) revealed that glucagon-stimulated hepatic mitochondrial oxidation (V~CS~) *in vivo*, increasing V~CS~ five-fold in WT mice, which could mostly be attributed to increased mitochondrial fat oxidation ([Figure 3a](#F3){ref-type="fig"}--[b](#F3){ref-type="fig"}). However, KO mice failed to increase hepatic mitochondrial oxidation in response to glucagon. Taken together these data suggest that glucagon stimulates hepatic mitochondrial oxidation through activation of InsP~3~R-I resulting in increased intra-mitochondrial calcium, which in turn stimulates mitochondrial dehydrogenases^[@R24]^. Consistent with this hypothesis, we observed a 7-fold increase in hepatic pyruvate dehydrogenase flux (V~PDH~) in WT but not KO mice infused with glucagon, without any difference in pyruvate kinase flux (V~PK~) ([Extended Data Figure 6n](#F9){ref-type="fig"}--[o](#F9){ref-type="fig"}). Glucagon stimulation of mitochondrial oxidation was not dependent on alterations in insulin: somatostatin-treated, basal insulin- and \~100 pM glucagon-infused WT mice exhibited similar increases in V~CS~ which were not observed in KO littermates ([Extended Data Figure 6p](#F9){ref-type="fig"}). *In vitro* studies confirmed an increase in oxygen consumption with glucagon stimulation in isolated hepatocytes from WT but not KO mice ([Extended Data Figure 6q](#F9){ref-type="fig"}), demonstrating that glucagon mediates these effects in a cell-autonomous manner.

Surprisingly, liver triglyceride concentrations did not differ between chow-fed WT and KO mice ([Extended Data Figure 6r](#F9){ref-type="fig"}), suggesting that physiologic glucagon may not promote sufficient mitochondrial fat oxidation in *ad lib* fed mice to alter hepatic triglyceride content. However, we hypothesized that chronic increases in hepatic mitochondrial oxidation induced by chronic glucagon treatment would reverse NAFLD and improve whole body insulin sensitivity. To that end, we performed chronic glucagon infusion studies in awake high fat fed (HFD) rats with diet-induced obesity, and found that after ten days of treatment, chronic glucagon infusion doubled rates of hepatic mitochondrial oxidation, which could be attributed to increased rates of hepatic fat oxidation ([Extended Data Figure 7a](#F10){ref-type="fig"}--[g](#F10){ref-type="fig"}). Two hours after withdrawal of glucagon, rats exhibited lower fasting plasma glucose and insulin concentrations associated with 50--90% reductions in hepatic triglyceride and diacylglycerol concentrations and marked reductions in protein kinase C-epsilon (PKCε) translocation despite similar food intake, body weight, and hepatic ceramide ([Extended Data Figure 7h](#F10){ref-type="fig"}--[o](#F10){ref-type="fig"}, [Supplementary Table 3](#SD3){ref-type="supplementary-material"}--[4](#SD3){ref-type="supplementary-material"}). Consistent with chronic increases in hepatic glycogenolysis, chronic glucagon infusion also resulted in reductions in liver glycogen content. In contrast to acute glucagon infusion, chronic glucagon infusion with withdrawal of glucagon treatment four hours before sacrifice lowered both hepatic acetyl- and malonyl-CoA content ([Extended Data Figure 7p](#F10){ref-type="fig"}--[r](#F10){ref-type="fig"}), with the reductions in malonyl-CoA potentially contributing to the observed reductions in hepatic lipid content due to suppression of hepatic lipogenesis^[@R25]^. Consistent with their lower hepatic lipid and acetyl-CoA content, chronic glucagon-infused rats manifested improved glucose tolerance and insulin sensitivity ([Extended Data Figure 7s](#F10){ref-type="fig"}--[v](#F10){ref-type="fig"}).

Finally, to determine whether InsP~3~R-I-dependent calcium signaling mediates the effect of chronic hyperglucagonemia to reverse NAFLD, we performed a four-week continuous infusion of glucagon in HFD WT and InsP~3~R-I KO mice. Despite unchanged body weight, food and water intake, and energetics, glucagon-treated WT mice exhibited 50--80% reductions in hepatic triglyceride/diacylglycerol -- but not ceramide -- content and PKCε translocation, resulting in a marked improvement in glucose tolerance, while each of these parameters was unchanged in KO mice ([Figure 3a](#F3){ref-type="fig"}--[h](#F3){ref-type="fig"}, [Extended Data Figure 8a](#F11){ref-type="fig"}--[j](#F11){ref-type="fig"}, [Supplementary Table 5](#SD3){ref-type="supplementary-material"}--[6](#SD3){ref-type="supplementary-material"}).

Collectively, these studies reveal that glucagon stimulates intrahepatic lipolysis through an InsP~3~R-I/CAMKII-dependent process, increasing hepatic acetyl-CoA content, which allosterically activates V~PC~ flux^[@R18]^, and that this phenomenon explains its acute, transcription-independent effect to stimulate gluconeogenesis *in vivo*. In addition, glucagon stimulates hepatic mitochondrial oxidation through InsP~3~R-I-mediated calcium signaling, and this process can be exploited by reversing hepatic insulin resistance with short-term continuous glucagon treatment. Thus these data provide a transcription-independent alternative mechanism ([Extended Data Figure 9](#F12){ref-type="fig"}) for glucagon action. Collectively these studies provide evidence in support of InsP~3~R-I as a potential target to treat NAFLD, NASH and T2D. Future clinical studies will be required to examine this possibility.

Online Methods {#S1}
==============

Animals {#S2}
-------

All protocols were approved by the Yale University Animal Care and Use Committee. Liver-specific InsP~3~R-I KO mice were generated as described^[@R16]^ and in all experiments, littermates were studied at 10--12 weeks of age. They were fed standard chow (Teklad \#2018) and housed on a 12 hr light/dark cycle in the Yale Animal Resources Center. To knock down ATGL in a liver-specific manner, an adeno-associated virus targeting ATGL (Vector BioLabs, 10^12^ gc per mouse) was administered by retro-orbital injection four weeks prior to studies. Male mice were used for *in vivo* studies, while both sexes were used for *in vitro* studies, unless otherwise specified. One week prior to *in vivo* studies, mice underwent surgery under isoflurane anesthesia to place a catheter in the jugular vein. Post-surgical recovery was confirmed by regaining the pre-surgical body weight prior to any *in vivo* studies. They were fasted overnight, unless otherwise stated, prior to *in vivo* studies. In the acute glucagon infusion studies, mice were given an intravenous infusion of glucagon (5 ng kg^−1^ min^−1^) for two hours, with tissue and plasma samples obtained after two hours of infusion. Mice were euthanized using IV pentobarbital at the conclusion of the terminal study. In the somatostatin infusion study, a 90 min jugular venous infusion of somatostatin (4 μg/\[kg-min\], 1:1 mix of somatostatin-14 and −28 concurrently with \[3-^13^C\] lactate and \[^2^H~7~\] glucose, as described below, was administered for a total of 90 min. During the somatostatin infusion, mice were also infused with insulin (2 mU kg^−1^ min^−1^) and glucagon (6 ng kg^−1^ min). In the acute high-dose glucagon experiment, mice were injected with 600 μg/kg glucagon and sacrificed 20 min later after isoflurane anesthesia. Blood was collected by cardiac puncture and liver was excised and freeze-clamped.

Mice infused chronically with glucagon were fed a high fat diet (Research Diets D12492) for four weeks, after which they were implanted with an Alzet pump providing glucagon continuously (0.15 ng min^−1^) for another 3.5 weeks, during which time they were continued on a high fat diet. They underwent CLAMS metabolic cage analysis to assess energetics and food and water intake during the second week of glucagon infusion. After an overnight fast, 3 weeks after implantation of the glucagon pumps, mice underwent an intraperitoneal glucose tolerance test and were subsequently refed. 48 hr later, after a 6 hr fast, they were sacrificed under isoflurane anesthesia for measurement of hepatic lipid content as described below.

For the chronic glucagon infusion studies in rats, 300 g male Sprague-Dawley rats were obtained from Charles River Laboratories and fed a safflower oil-based high fat diet (HFD, 60% calories from fat, Dyets \#112245) for 4 weeks. During week 3 of the diet, rats underwent surgery under isoflurane anesthesia to place catheters in the jugular vein and carotid artery, and recovery was confirmed by regaining the pre-surgical body weight prior to *in vivo* studies. After four weeks on HFD, rats were placed in a soft plastic harness to protect their catheters and infused continuously for 10 days with glucagon (5 ng kg^−1^ min^−1^), total volume 5 ml kg^−1^ day^−1^). The glucagon infusion was either continued throughout the terminal study (PINTA) or discontinued two hours before the start of the terminal study (GTT with hepatic lipid/acetyl-CoA/glycogen measurements), in separate groups of rats, as specified in the figure legends. Rats were fasted for 8 hr prior to sacrifice with IV pentobarbital.

In vivo studies {#S3}
---------------

In all *in vivo* mouse studies, blood was collected from the tail vein, with the exception of portal vein glucagon measurements, in which a needle was inserted into the portal vein of anesthetized mice to collect blood. In the rat studies, blood was collected from the jugular venous catheter. In both species, samples were immediately centrifuged (12,000 rpm) to separate plasma from red blood cells. We employed PINTA analysis of hepatic mitochondrial fluxes in both rats and mice^[@R26]^. Briefly, mice were infused with a two- hour primed (5 min, 3X)-continuous infusion of \[3--13C\] lactate (40 μmol kg^−1^ min^−1^) and \[1,2,3,4,5,6,6-^2^H~7~\] glucose (0.1 mg kg^−1^ min^−1^). Rats were infused with lactate at the same rate, as well as \[3--3H\] glucose (0.1 μCi kg^−1^ min^−1^). At the conclusion of the study, animals were euthanized with IV pentobarbital.

In mice, hepatic glycogenolysis was assumed to be negligible due to their prolonged (16 hr) fasted state and their low hepatic glycogen content ([Extended Data Figures 2a](#F5){ref-type="fig"}, 10d, and 14f). Total glucose turnover (i.e. hepatic glucose production) was measured by determining the specific activity of \[^3^H\] glucose in plasma using a scintillation counter, and the V~PC~/V~HGP~ ratio was calculated using the equation $\frac{V_{PC}}{V_{HGP}} = \frac{G2}{{XFE}^{2}}$, where G2 represents the \[m+2\] glucose enrichment corrected for any \[m+2\] glucose synthesized from ^13^C~2~-labeled trioses: $Corrected\ m + 2\ glucose = G2 = Measured\ \left\lbrack m + 2 \right\rbrack\ glucose - 2*C4C5C6\ \lbrack{m + 2}\rbrack glucose$, and XFE represents the fractional triose enrichment: $XFE = \frac{1}{1 + \frac{G1}{2*G2}}$, where G1 represents the measured \[m+1\] glucose and G2 as described above. To calculate absolute V~PC~ flux, we multiplied the measured HGP by the ratio V~PC~/V~HGP~. The ratio of hepatic V~PC~/V~CS~ flux was calculated as $\frac{V_{PC}}{V_{CS}} = \frac{\left\lbrack 5 - {}^{13}{\left. C \right\rbrack\ glucose} \right.}{2*\left\lbrack 4 - {}^{13}{\left. C \right\rbrack\ glucose} \right.} - 1$, and calculated absolute V~CS~ by dividing V~PC~ by V~PC~/V~CS~. The derivations of each equation are described in detail in our previous study^[@R26]^. We corrected for the possible contribution of \[13C\] bicarbonate to label the TCA cycle as we have described^[@R27]^.

We measured the ratio $\frac{V_{PDH}}{V_{CS}} = \frac{\lbrack{4 - {}^{13}C}\rbrack glutamate}{\left\lbrack 3 - {}^{13}{\left. C \right\rbrack\ alanine} \right.}$^[@R28]^ and calculated absolute V~PDH~ by multiplying this ratio by the measured V~CS~. Finally, the ratio of V~PK~ -- assuming minimal malic enzyme flux -- to (V~PC~+V~PDH~) was calculated as $\frac{V_{PK}}{V_{PC} + V_{PDH}} = \frac{\left\lbrack 2 - {}^{13}{\left. C \right\rbrack\ alanine} \right.}{\left\lbrack 5 - {}^{13}{\left. C \right\rbrack\ glucose} \right.}$^[@R29]^. Absolute V~PK~ fluxes were then determined by multiplying $\frac{V_{PK}}{V_{PC} + V_{PDH}}$ by the sum of V~PC~ and V~PDH~. As we have described^[@R26]^, $\frac{V_{PC}}{V_{CS}}$ can be expanded to account for pyruvate recycling: $\frac{{V_{PC} + \frac{1}{2}\ V}_{PK}}{V_{CS}} = \frac{\left\lbrack 5 - {}^{13}{\left. C \right\rbrack\ glucose} \right.}{2*\left\lbrack 4 - {}^{13}{\left. C \right\rbrack\ glucose} \right.} - 1$. In this study we measured a maximum $\frac{V_{PK}}{V_{PC} + V_{PDH}}$ of 0.4, indicating that the maximal $\frac{V_{PK}}{V_{PC}}$ is 0.4. A $\frac{V_{PK}}{V_{PC}}$ at this maximal value would generate a 17% underestimation of $\frac{V_{PC}}{CS}$. *Ex vivo* NMR analysis was used to confirm PINTA measurements of flux ratios as we have described^[@R26]^.

In rats, HGP was measured by measuring the plasma glucose \[m+7\] atom percent enrichment (APE) by gas chromatography/mass spectrometry (GC/MS) and using these data to calculate HGP according to the equation HGP = (Tracer APE/Plasma APE -- 1) \* infusion rate. All other flux ratios and absolute fluxes were measured using the equations given above.

In the glucose tolerance tests, rodents were injected with 1 g kg^−1^ 50% dextrose (rats) or 10% dextrose (mice) intraperitoneally. Blood samples were taken through the venous catheter (rats) or by tail bleeding (mice) for measurement of plasma glucose and insulin concentrations as described below.

Biochemical analysis {#S4}
--------------------

Plasma glucose concentrations were measured using the YSI Glucose Analyzer. Plasma insulin was measured by ELISA (Mercodia), while glucagon was measured in samples immediately spiked with aprotinin (0.5 mg μL^−1^) whole blood by RIA by the Yale Diabetes Research Core. Plasma NEFA concentrations were measured using the Wako NEFA assay, while plasma glycerol^[@R30]^ and plasma and liver amino acid concentrations^[@R17]^ were measured by GC/MS. Liver acetyl- and malonyl-CoA^[@R18]^ (standard curve R2=0.999 and 0.999), long-chain CoA^[@R31]^, DAG^[@R31]^, and ceramide^[@R31]^ concentrations were measured by LC-MS/MS, hepatic glycogen content following amyloglucosidase digestion^[@R32]^, and TAG concentrations enzymatically^[@R33]^. cAMP concentrations were measured using the Enzo Life Sciences Direct cAMP ELISA. Protein concentrations were measured by Western blot, using antibodies from Santa Cruz (PC, PEPCK, CAMKII), Cell Signaling (ATGL, pCAMKIV, CAMKIV, pCRTC2, CRTC2, pACC, ACC, pAMPK, AMPK, pHSL, HSL, GAPDH, and β-actin), Novus Biologicals (pCAMKII), Abcam (pATGL), LSBio (pInsP~3~R-I), and BD Transduction Laboratories (InsP~3~R-III and PKCε). The antibody to pATGL was kindly provided by Dr. Hei Sook Sul, while the antibody to total InsP~3~R-I was custom-made using an epitope against the last 18 amino acids of InsP~3~R-I. The antibody to InsP3R-II was generously donated by the Wojcikiewicz Lab (SUNY Upstate Medical University). The antibody to CRTC2 as well as hepatocyte control samples (WT±glucagon and CRTC2 KO) for antibody validation were a kind gift of Dr. Marc Montminy. To measure protein expression in isolated hepatocytes, a Mitochondria Isolation Kit (Thermo Scientific) was used to separate cells into cytoplasmic (c.) and crude mitochondrial (c.m.) fractions, the latter containing both mitochondria and closely-apposed mitochondria-associated proteins. The final spin was conducted at 1000 rpm for 15 min at 4°C to obtain a cleaner mitochondrial fraction with reduced lysosomal contamination. Mitochondria were lysed in 2% CHAPS in tris-buffered saline (TBS), and the protein concentration was measured with the bicinchoninic acid assay (Thermo Scientific). Samples for all Western blot analyses were loaded on 4 to 12% gradient gels (NuPage gels, Life Technologies) and run with MOPS buffer. Protein was transferred to polyvinylidene difluoride membranes by wet transfer. After blocking with 5% milk in TBS with 0.1% Tween 20, primary antibodies were applied overnight. Gluconeogenic gene mRNA expression was measured by qPCR^[@R34]^ using primers with the following sequences:

β-actin: F, CCAGATCATGTTTGAGACCTTC, R, CATGAGGTAGTCTGTCAGGTCC

PEPCK: F, CAGGAAGTGAGGAAGTTTGTGG, R, ATGACACCCTCCTCCTGCAT

G6Pase: F, GAAGGCCAAGAGATGGTGTGA, R, TGCAGCTCTTGCGGTACATG

PC: F, AGATGCACTTCCATCCCAAG, R, CCTTGGTCACGTGAACCTTT

In vitro studies {#S5}
----------------

Primary hepatocytes were isolated by the Yale Liver Center from wild-type and InsP~3~R-I KO mice and plated on glass coverslips coated with Rat Collagen Type I. Cells were loaded with the cytosolic Ca^2+^ indicator dye, Fluo-4 AM (Thermo Fisher Scientific), or the mitochondrial matrix-targeted Ca^2+^ indicator, Rhod-2 AM (Thermo Fisher Scientific) for 30 minutes at 37oC. Ca^2+^ imaging experiments were performed in 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES)-buffered balanced salt solution (25 mM HEPES, 121 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO~4~, 1.2 mM KPO~4~, 5 mM NaHCO~3~, 2.0 mM CaCl~2~, 10 mM glucose, pH 7.4) with or without the PKA inhibitor H-89 (25 μM) or the PLC inhibitor U73122 (10 μM) two to four hr following initial plating. Coverslips were transferred to a custom-built perfusion chamber on the stage of a Zeiss LSM 710 confocal microscope (Carl Zeiss Microscopy, Thornwood, NY). Cytosolic and mitochondrial signals were monitored in Fluo-4 AM and Rhod-2-loaded cells, respectively using stimulation with 100 nM glucagon (Sigma-Aldrich) or 100 nM vasopressin (Sigma-Aldrich) with a 20x objective lens. Changes in fluorescence were normalized by the initial fluorescence before addition of agonist and were expressed as F/F0.

For *in vitro* glucose production and lipolysis studies, primary mouse hepatocytes were isolated by the Yale Liver Center. Following removal of cell debris by Percoll density gradient centrifugation, cells were plated on 6-well collagen-I coated dishes (4.0×105 cells/well) in 2 ml recovery media (DMEM high glucose containing 10% FBS, 2% penicillin-streptomycin, 100 nM dexamethasone, 1 nM insulin, and 10 mM HEPES). After incubation for 6 hr at 37°C and 5% CO~2~, the attached cells were washed once in 1x PBS and then incubated overnight in 2 ml low glucose culture media (DMEM low glucose supplemented with 10% FBS, 2% penicillin-streptomycin and 10 mM HEPES for glucose production studies) or Serum Free Low Glucose Culture Media (DMEM low glucose supplemented with 0.5% fatty acid free BSA, 2% penicillin-streptomycin and 10 mM HEPES for lipolysis assays). The next morning, cells were washed twice in 1x PBS and culture media replaced with 2 mL glucose production media (DMEM base media supplemented with 0.5% fatty acid free BSA, 20 mM sodium lactate, 2 mM sodium pyruvate and 10 mM HEPES, pH 7.4) or serum-free low glucose culture media (lipolysis assay) in the presence of 100 nM glucagon or vehicle control. After incubation for 8 hr at 37°C and 5% CO~2~, cell culture media was collected for analysis of glucose, NEFA, and glycerol concentrations as described above. V~PC~ was determined by measuring V~PC~/V~EGP~ by PINTA as described above using 300 μL of the collected media and multiplying this ratio by the measured glucose production rate. In a subset of studies, cells were incubated for 8 hr during the glucose production assay in media containing one of the following agents (all dissolved in 0.5% DMSO), or 0.5% DMSO vehicle: 20 μM ET-18-OCH~3~ (Santa Cruz), 100 μM U-73122 (Sigma), 30 nM thapsigargin (Sigma), 100 nM vasopressin (Sigma), 50 μM 2-APB (R&D Systems), 70 μM caffeine (Sigma), 1 mM malic enzyme inhibitor hydroxymalonate (Sigma). To inhibit PKA, hepatocytes were incubated in H-89 dichloroacetate hydrate (Sigma, 25 μM) dissolved in media, or media lacking H-89 as a control. In the insulin treatment studies, hepatocytes were incubated in 1 nM insulin with 5% BSA and glucose production media for the duration of the glucose production assay. In the *in vitro* atglistatin study, hepatocytes were incubated in 10 μM atglistatin in 0.1% EtOH, or 0.1% EtOH vehicle. All values were normalized to total protein content determined from whole-cell lysates by a BCA protein assay (Thermo Fisher Scientific) according to the manufacturer's instructions and expressed as fold change versus vehicle-treated cells.

To assess oxygen consumption, primary mouse hepatocytes were isolated as described above and plated on collagen-I coated XF24 V7 cell culture plates (1.2×104 cells per well) in 2 mL recovery media as previously described^[@R35]^. Following incubation for 6 hr at 37°C and 5% CO~2~, the cells were washed twice with 1 ml low glucose culture media and incubated overnight in 250 μl low glucose culture media at 37°C and 5% CO~2.~ The following morning, cells were washed with XF24 assay media (DMEM base media containing 1.0 mM pyruvate, 2 mM glutamine and 5.5 mM glucose, pH 7.4). 500 μL of XF24 assay media was added to each well and plates were equilibrated at 37°C for 1 h. Four measurements of basal oxygen consumption rates (picomoles per minute) were recorded on a Seahorse Bioscience XFe 24 Analyzer (Seahorse Biosciences) using an instrument protocol of 3-minute mix, 2-minute wait, and 3-minute measure. After baseline measurements, glucagon (or vehicle) was injected at a final concentration of 100 nM and oxygen consumption was recorded using the same instrument protocol. Ten measurements were taken following injection and the average of eight measurements were used for subsequent analyses. Oxygen consumption rates were normalized to total protein content and expressed as fold change compared to vehicle-treated cells. Experiments were repeated three times using 3--4 mice per genotype.

Statistics and reproducibility {#S6}
------------------------------

Group sizes of 6--10 per group were chosen to detect moderate to large (\>40%) differences with \~40% standard deviations. Comparisons were performed using GraphPad Prism 7. Each *in vivo* experiment was performed with the number of replicates specified in the figure legends. All data obtained are shown, with the exception of several western blots in which case one representative image is shown, but all data are shown in the quantification. The two-tailed paired (when comparing the same animals under multiple conditions) or unpaired Student's t-test (when comparing different animals) was used to compare data sets. *P*-values less than 0.05 were considered significant. Comparisons were performed using GraphPad Prism 7.

Extended Data {#S7}
=============

![Glucagon acutely stimulates hepatic gluconeogenesis by increasing hepatic acetyl-CoA content and pyruvate carboxylase flux. (a) Body weight (n=11). (b) Liver InsP~3~R-I protein expression (n=5). Blots in [Figures 1f](#F1){ref-type="fig"} and [2a](#F2){ref-type="fig"}, and Extended Data Figures 1b, 1d, 1f, [3f](#F6){ref-type="fig"}, [3g](#F6){ref-type="fig"}, and [4a](#F7){ref-type="fig"} were stripped and re-probed for all proteins of interest. \**P*\<0.05 vs. InsP~3~R-I KO mice not treated with glucagon. (c) InsP~3~R protein expression in cytosolic ("c.") and crude mitochondrial ("c.m.") fractions from primary hepatocytes, in which VDAC was examined as a marker for mitochondrial protein content, and calreticulin as a marker for non-mitochondria-associated membrane protein. On the right, Liver InsP~3~R-I phosphorylation in mice infused with glucagon (n=5). The blot for total InsP~3~R-I is duplicated from Extended Data Figure 1b. (d) Liver CRTC2 phosphorylation (n=5). The CRTC2 phosphorylation gel was stripped and re-probed to assess HSP90 (loading control). (e) Liver CAMKIV phosphorylation ± a 2 hr acute infusion of glucagon (n=5). (f) Liver glycogen content (n=5 WT--glucagon, otherwise n=6). No differences were observed using one-way ANOVA with Bonferroni's multiple comparisons test. (g)-(i) Plasma \[m+1\], \[m+2\], and \[m+7\] plasma glucose enrichment during a 120 min infusion of \[3-^13^C\] lactate and \[^2^H~7~\] glucose (n=5 WT and 6 KO, with the exception of panel (i), in which n=4 WT+glucagon at 100 and 110 min). (j)-(k) Plasma total amino acid and alanine concentrations (n=5 WT and 6 KO). In panels j-k, groups were compared before and after glucagon by the 2-tailed paired Student's t-test, and genotypes were compared by the 2-tailed unpaired Student's t-test. (l)-(m) Liver total amino acid and alanine concentrations (n=5). (n)-(o) *In vitro* glucose production (n=9) and V~PC~ flux (n=4) in isolated hepatocytes. (p)-(q) *In vitro* glucose production (n=9) and V~PC~ flux (n=4) in isolated hepatocytes with and without 150 pM insulin. Basal data (no insulin) are duplicated from panels n and o. (r)-(s) *In vitro* glucose production (n=8) and V~PC~ flux (n=3) in isolated hepatocytes with and without a malic enzyme inhibitor. \*\**P*\<0.01, \*\*\*\**P*\<0.0001 vs. WT-glucagon-ME inhibitor. (t)-(v) Plasma c-peptide, glucagon, and glucose concentrations in mice (n=6 WT and 7 KO) treated with somatostatin, basal insulin, and glucagon. Comparisons before and after glucagon used the 2-tailed paired Student's t-test. (w)-(x) Endogenous glucose production and V~PC~ (n=6 WT and 7 KO). In all panels, unless otherwise stated, comparisons with and without glucagon, insulin, or malic enzyme inhibitor, and WT vs. KO were performed using the 2-tailed unpaired Student's t-test. In all panels where comparisons were performed (i.e. all panels with the exception of g-i), if no p-value is shown, groups were not significantly different. In all panels, the mean±S.E.M. are shown.](nihms-1549977-f0004){#F4}

![Glucagon-stimulated glucose production requires activation of the PLC and PKA pathways, converging to activate InsP~3~ signaling. *In vitro* glucose production and V~PC~ flux in isolated hepatocytes with and without ET-18-OCH~3~ (n=3), U-73122 (n=3, with the exception of KO-glucagon-U-73122, in which n=2), H-89 (n=6), vasopressin (n=3), 2-APB (n=3), caffeine (n=3), KN-93 (n=6), and thapsigargin (n=3). In all panels, \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 vs. WT-glucagon-drug; §*P*\<0.05, §§*P*\<0.01, §§§*P*\<0.001 vs. WT +glucagon -drug by the 2-tailed unpaired Student's t-test. If no statistical comparison is denoted, the groups were not significantly different. The mean±S.E.M. is shown.](nihms-1549977-f0005){#F5}

![Glucagon stimulates hepatic glucose production independently of transcriptional regulation and plays a key role in maintenance of blood glucose during a prolonged fast. (a)-(c) Liver PC, PEPCK, and G6Pase mRNA expression (n=5). (d)-(e) Liver PC and PEPCK protein (n=5 with the exception of KO+glucagon, where n=6). (f)-(g) Liver pACC/ACC and pAMPK/AMPK (n=5). Blots in [Figures 1f](#F1){ref-type="fig"} and [2a](#F2){ref-type="fig"}, and [Extended Data Figures 1b](#F4){ref-type="fig"}, [1d](#F4){ref-type="fig"}, [1f](#F4){ref-type="fig"}, 3f, 3g, and [4a](#F7){ref-type="fig"} were stripped and re-probed for all proteins of interest. (h) Plasma NEFA (n=5, with the exception of KO+glucagon, where n=6). (i) Liver malonyl-CoA (n=6). (j)-(l) Plasma glucose, insulin, and glucagon concentrations in 48 hr fasted mice (in all panels j-o, n=5). (m)-(o) Liver long-chain-, acetyl-, and malonyl-CoA content. In all panels, genotypes and groups +/− glucagon were compared using the 2-tailed unpaired Student's t-test. If no statistical comparison is denoted, the groups were not significantly different. In all panels, the mean±S.E.M.](nihms-1549977-f0006){#F6}

![Glucagon acutely stimulates gluconeogenesis by activating intrahepatic, but not white adipose tissue, lipolysis. (a) Liver HSL phosphorylation (n=5). Blots in [Figures 1f](#F1){ref-type="fig"} and [2a](#F2){ref-type="fig"}, and [Extended Data Figures 1b](#F4){ref-type="fig"}, [1d](#F4){ref-type="fig"}, [1f](#F4){ref-type="fig"}, [3f](#F6){ref-type="fig"}, [3g](#F6){ref-type="fig"}, and 4a were stripped and re-probed for all proteins of interest. In panels a-c, groups were compared using the 2-tailed unpaired Student's t-test. (b)-(c) *In vitro* NEFA and glycerol production from isolated hepatocytes (n=14 WT and 15 KO). (d) Plasma NEFA concentrations in mice treated with somatostatin, replacement basal insulin, and glucagon (n=5 WT and 6 KO). No significant differences were observed between genotypes using the 2-tailed unpaired Student t-test, or before vs. after glucagon using the 2-tailed paired Student's t-test. (e)-(f) NEFA production and V~PC~ in isolated hepatocytes incubated in the ATGL inhibitor atglistatin (n=6). (g)-(n) NEFA production from isolated hepatocytes treated with ET-18-OCH~3~ (n=3), U-73122 (n=3), H-89 (n=6), vasopressin (n=3), KN-93 (n=6), 2-APB (n=3), caffeine (n=3), and thapsigargin (n=3). In all panels, \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 versus the same genotype -glucagon -drug; §*P*\<0.05, §§ *P*\<0.01, §§§ *P*\<0.001 versus the same genotype +glucagon -drug by the 2-tailed unpaired Student's t-test. If no statistical comparison is denoted, the groups were not significantly different. Error bars represent the S.E.M.](nihms-1549977-f0007){#F7}

![Glucagon requires InsP~3~-mediated intrahepatic lipolysis to promote V~PC~ and hepatic gluconeogenesis. (a) Body weight in mice treated with an adeno-associated virus to knock down liver ATGL (n=6). (b) Representative western blots. Blots from the same tissue (liver or WAT) were stripped and reprobed for all proteins shown. (c) WAT and liver ATGL protein expression (n=4, with the exception of KO+ATGL knockdown, in which n=6). (d)-(e) Hepatic PC and PEPCK protein expression (n=6 WT and KO+ATGL knockdown, in other groups, n=4). (f)-(h) Plasma glucagon, NEFA and glycerol concentrations in mice treated with an adeno-associated virus to knock down ATGL in a liver-specific manner (n=6, with the exception of WT+ATGL knockdown and KO, in which n=5). Groups were compared before and after glucagon by the 2-tailed unpaired Student's t-test. (i)-(j) Liver glycogen and malonyl-CoA content (n=6 other than WT+ATGL knockdown, in which n=5). All comparisons were performed using the 2-tailed unpaired Student's t-test, unless otherwise stated. If no statistical comparison is denoted, the groups were not significantly different. Error bars represent the S.E.M.](nihms-1549977-f0008){#F8}

![Glucagon stimulates mitochondrial oxidation through hepatocellular calcium signaling. (a) Representative mitochondrial response to glucagon, which was added where denoted by the "glucagon" bar. (b) Maximum mitochondrial response to glucagon (n=324 WT and 167 KO). Groups in panels b, d, f, and h were compared by the 2-tailed unpaired Student's t-test. (c) Representative cytosolic response to glucagon. (d) Maximum cytosolic response to glucagon (n=146 WT and 175 KO). (e) Representative mitochondrial response to the InsP~3~R agonist vasopressin. (f) Amplitude of the cytosolic response to vasopressin (n=73 WT and 42 KO). (g) Representative cytosolic response to vasopressin. (h) Amplitude of the cytosolic response to vasopressin (n=119 WT and 53 KO). (i) Representative mitochondrial responses to glucagon (added where denoted by the bar) in WT hepatocytes incubated in the PKA inhibitor H-89 or the PLC inhibitor U-73122. (j) Amplitude of the mitochondrial response (n=79 control, 39 H-89, and 127 U-73122). Groups were compared to the control in panels j and l, and m using the 2-tailed unpaired Student's t-test. (k) Representative cytosolic responses to glucagon±H-89 or U-73122. (l) Amplitude of the cytosolic response (n=182 control, 27 H-89, and 187 U-73122). (m) Percentage of cells with a cytosolic response (\>110% baseline) to glucagon±H-89 or U-73122 (n=11 control, 8 H-89, and 3 U-73122). (n)-(o) Hepatic PDH and PK flux *in vivo* (n=5 WT-glucagon, 6 WT+glucagon, 6 KO-glucagon, 5 KO+glucagon). In panels n-o, groups were compared (with vs. without glucagon, and WT vs. KO) using the 2-tailed unpaired Student's t-test. (p) Liver V~CS~ in mice infused with somatostatin, basal insulin, and glucagon (n=5). (q) *In vitro* oxygen consumption in isolated hepatocytes incubated±100 nM glucagon (n=113 WT-glucagon, 144 KO-glucagon, 149 WT+glucagon, 210 KO+glucagon). (r) Liver triglyceride content (without glucagon infusion) (n=11). In all panels, if no statistical comparison is denoted, the groups were not significantly different. Error bars represent the S.E.M.](nihms-1549977-f0009){#F9}

![Chronic increases in mitochondrial oxidation with a 10-day glucagon infusion lead to reversal of NAFLD and improvements in glucose tolerance. (a) Plasma glucagon concentrations on the last day of infusion. In all panels in this figure, n=6. (b) Hepatic V~CS~ flux. In panels (b)-(g), measurements were performed while the glucagon infusion continued. (c)-(d) V~PC~ V~EGP~^−1^ and V~PC~ V~CS~^−1^ ratios. (e)-(g) Hepatic V~PDH~, V~FAO~, and V~PK~ rates. (h) Food intake during the glucagon infusion, determined twice during the 10 day infusion (days 4 and 9) by weighing the food in the cage; the data points are the averages of the two food intake measurements for each animal. (i) Body weight after 10 days of glucagon or saline infusion. (j)-(k) 6 hr fasted plasma glucose and insulin concentrations measured two hours after cessation of the glucagon infusion. (l)-(n) Liver TAG (n=6), DAG (n=8), and ceramide (n=8) concentrations. (o) Hepatic PKCε translocation (n=6 control and 7 glucagon). (p)-(r) Liver glycogen (n=6), acetyl-CoA (n=8), and malonyl-CoA content (n=8). (s)-(t) Plasma glucose concentrations and area under the curve during an intraperitoneal glucose tolerance test which began 2 hrs after completing a 10 day continuous infusion of glucagon or saline (n=6). In panels s and u, \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001. Data are the mean±S.E.M. (u)-(v) Plasma insulin and insulin area under the curve during the GTT. In all panels, error bars represent the S.E.M, and groups were compared using the 2-tailed unpaired Student's t-test. If no statistical comparison is denoted, the groups are not significantly different.](nihms-1549977-f0010){#F10}

![Chronic glucagon treatment reverses NAFLD and glucose intolerance in WT but not InsP~3~R-I KO mice. (a) Body weight (n=10 WT-glucagon, 11 WT+glucagon, 8 KO-glucagon, and 8 KO+glucagon). (b)-(c) Food and water intake. In panels (b)-(g), n=8 WT-glucagon, 9 WT+glucagon, 7 KO-glucagon, 8 KO+glucagon. (d) Energy expenditure. (e)-(f) Oxygen consumption and carbon dioxide production. (g) Activity. (h) Plasma NEFA. In panels (h)-(j), n=10 WT-glucagon, 11 WT+glucagon, 8 KO-glucagon, 8 KO+glucagon. (i)-(j) Glucose and insulin area under the curve during an intraperitoneal glucose tolerance test. In all panels, the mean±S.E.M. is shown. Statistical comparisons were performed using the 2-tailed unpaired Student's t-test. If no statistical comparison is denoted, the groups were not significantly different.](nihms-1549977-f0011){#F11}
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![Glucagon acutely stimulates hepatic gluconeogenesis by increasing hepatic acetyl-CoA content and V~PC~. (a)-(c) Plasma glucose, insulin, and glucagon concentrations before and at the end of a 2 hr intravenous infusion of glucagon (n=7). (d)-(f) Hepatic cAMP concentrations, protein kinase A activity, and CAMKII phosphorylation (n=5, with the exception of WT --glucagon in panel (e), in which n=4). Blots in Figures 1f and [2a](#F2){ref-type="fig"}, and [Extended Data Figures 1b](#F4){ref-type="fig"}, [1d](#F4){ref-type="fig"}, [1f](#F4){ref-type="fig"}, [3f](#F6){ref-type="fig"}, [3g](#F6){ref-type="fig"}, and [4a](#F7){ref-type="fig"} were stripped and re-probed for all proteins of interest. (g)-(h) HGP (n=6 WT and 5 KO) and V~PC~ (n=5 WT and 6 KO). (i)-(j) Hepatic long-chain- (n=5 WT-glucagon, 6 WT+glucagon, and 6 KO) and acetyl-CoA content (n=6). In all panels, the mean±S.E.M. is shown. Groups were compared before and after glucagon (panels a-c, g, and h) by the 2-tailed paired Student's t-test, and separate animals (+/− glucagon in panels d-f, i, and j, and WT vs. KO animals in all panels) were compared by the 2-tailed unpaired Student's t-test.](nihms-1549977-f0001){#F1}

![Glucagon requires InsP~3~-mediated intrahepatic lipolysis to promote V~PC~ and HGP. (a) ATGL S406 phosphorylation (n=5). Blots in [Figures 1f](#F1){ref-type="fig"} and 2a, and [Extended Data Figures 1b](#F4){ref-type="fig"}, [1d](#F4){ref-type="fig"}, [1f](#F4){ref-type="fig"}, [5f](#F8){ref-type="fig"}, [5g](#F8){ref-type="fig"}, and [7a](#F10){ref-type="fig"} were stripped and re-probed for all proteins of interest. (b) Glucose production in hepatocytes (n=6 mice per group) incubated in the ATGL inhibitor atglistatin and/or glucagon. \*\*\*\**P*\<0.0001 vs. WT-glucagon-atglistatin, §§§§ vs. WT+gluagon-atglistatin. (c)-(d) Plasma glucose and insulin concentrations in mice treated with an adeno-associated virus to knock down ATGL in a liver-specific manner. In panels (c)-(h), n=6 WT, 5 WT+ATGL knockdown, 6 KO±ATGL knockdown). (e)-(f) Liver long-chain- and acetyl-CoA concentrations following a 2 hr glucagon infusion. (g)-(h) Hepatic glucose production and hepatic V~PC~. In all panels, the mean±S.E.M. is shown. Groups were compared before and after glucagon (panels c and d) by the 2-tailed paired Student's t-test, and groups in all other panels (as well as the four separate groups in panels c and d) were compared by the 2-tailed unpaired Student's t-test.](nihms-1549977-f0002){#F2}

![Chronic increases in mitochondrial oxidation with a continuous 3.5 week glucagon infusion reverse of hepatic steatosis and improve glucose tolerance in an InsP~3~R-I-dependent manner. (a)-(b) Liver V~CS~ and V~FAO~ with acute glucagon infusion (n=5 WT-glucagon, 6 KO-glucagon, 6 WT+glucagon, 5 KO+glucagon). (c) Liver TAG concentrations in HFD mice chronically infused with glucagon (n=9 WT-glucagon, 8 WT+glucagon, 8 KO-glucagon, 7 KO+glucagon). (d) Liver ceramide (n=6). (e) Liver DAG (n=9 -glucagon, 7 +glucagon). (f) PKCε translocation (n=6). (g)-(h) Plasma glucose and insulin during a glucose tolerance test (n=10 WT-glucagon, 11 WT+glucagon, 8 KO-glucagon, 8 KO+glucagon). In all panels, the mean±S.E.M. is shown. Groups were compared using the 2-tailed unpaired Student's t-test.](nihms-1549977-f0003){#F3}
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